Director/PDMR Shareholding

RNS Number : 6293A

AstraZeneca PLC

02 April 2012

 



Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

The interest of David Brennan, a Director of the Company, in AstraZeneca PLC ordinary shares, has changed as detailed below. 

On 30 March 2012, Mr Brennan was granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares.  A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2011 which is available on the Company's website www.astrazeneca.com.

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Award price per share
David Brennan	22,219	133,318	2805p

The AZIP award is subject to a four-year performance period (1 January 2012 to 31 December 2015) and a subsequent four-year holding period (1 January 2016 to 31 December 2019). The performance hurdle that applies to the AZIP award relates to dividends and dividend cover.

The AZPSP award is subject to a three-year performance period (1 January 2012 to 31 December 2014). The performance measures that apply to the AZPSP award relate to relative total shareholder return and cash flow.

Mr Brennan has interests in both the ordinary shares and the American Depositary Shares (ADSs) of AstraZeneca PLC.  One ADS equals one ordinary share.

As a result of these transactions, Mr Brennan has an interest in 734,270 ordinary shares and 83,344 AstraZeneca ADSs, which together represent approximately 0.06% of the Company's issued ordinary capital.

A C N Kemp

Company Secretary

2 April 2012

 

END

 

 

RDSUURSRUOASRAR